Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure.
about
Novel GPCR paradigms at the μ-opioid receptorGaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessorsAgents with vasodilator properties in acute heart failure: how to design successful trialsPotential new drug treatments for congestive heart failure.Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR)G protein-coupled receptors in cardiac biology: old and new receptorsBiased signaling favoring gi over β-arrestin promoted by an apelin fragment lacking the C-terminal phenylalanineThe potential for selective pharmacological therapies through biased receptor signalingNew Drugs You Are Going to Read About: Serelaxin, Ularitide, TRV027.International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury.RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches.The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimersArginine vasopressin enhances cell survival via a G protein-coupled receptor kinase 2/β-arrestin1/extracellular-regulated kinase 1/2-dependent pathway in H9c2 cells.Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor.β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction.The β-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calciumERK and β-arrestin interaction: a converging point of signaling pathways for multiple types of cell surface receptors.Acute Heart Failure TreatmentFunctionally biased signalling properties of 7TM receptors - opportunities for drug development for the ghrelin receptor.Biased agonism as a mechanism for differential signaling by chemokine receptors.βArrestins in cardiac G protein-coupled receptor signaling and function: partners in crime or "good cop, bad cop"?Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and PathologyMinireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice.Dynamic mass redistribution analysis of endogenous β-adrenergic receptor signaling in neonatal rat cardiac fibroblasts.Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2.Treatment of acute heart failure in the emergency department.Maladaptive modifications in myofilament proteins and triggers in the progression to heart failure and sudden death.Non-canonical signalling and roles of the vasoactive peptides angiotensins and kinins.Recent developments in biased agonism.Novel drug mechanisms in development for heart failure.Apelin receptor: its responsiveness to stretch mechanisms and its potential for cardiovascular therapy.Vasodilators in Acute Heart Failure: Review of the Latest Studies.Autonomic Dysregulation as a Therapeutic Target for Acute HF.The mass action equation in pharmacology.Agents with vasodilator properties in acute heart failure.AT1 receptor signaling pathways in the cardiovascular system.
P2860
Q26864286-43E2288C-11B2-4E37-A8D8-899E076998D1Q27005640-9B888C14-246A-46B2-A088-118EFDA7EB9CQ28084239-5A7D1C2E-0700-4B7F-868B-00C3143113A1Q30251531-F37B7B30-4D3A-4E38-BC62-822EE45F92DBQ33565687-B5F12266-E553-4203-B4EE-B7D99578E177Q33619504-F06B4A94-CC63-4112-8A0E-3F93BEF6FA6AQ33639685-DD19C433-86B4-437C-AF6B-42BB80C8018CQ34107370-D24DB514-7302-498A-A3BA-B11B0777D44FQ34402658-2A8233AD-AD29-4CC7-B3D6-6C50449FD181Q35899860-384ED2E1-D3C4-40EB-8B0D-A20818123B70Q36241932-443C5A51-7D60-43DA-978A-E46BE1E1EBCBQ36312524-49C3C932-8039-401C-A3AA-0724488B06AFQ36551388-D1C7F06A-F9E4-43FD-924E-A46C2F764B1DQ36967299-224131F2-CF9E-4CA8-85BF-0A6832A65479Q37027076-9DD23DA0-C96F-434B-B162-B4A2BFC18DF1Q37062531-42866F30-04ED-4DF4-9601-5030C5C54B5AQ37102508-EC05D0B6-81A5-4DC4-ADFF-4173DFBCE0A0Q37142798-443E58C1-7AF5-4301-8767-5E6D90DF3B37Q37156463-F32CBC4C-5AE0-49A2-A19E-2376EC7A4CCFQ37291720-A6C89FE6-B609-454D-98BC-2F62ECE9B258Q37337832-9078F5C6-0467-45D9-A391-B9E19F5CBFF5Q37368610-2527263D-14E5-4C65-BAA4-638225B6326EQ37421052-0BA7E38D-4593-4380-8A0A-A09BA1625CC6Q37551908-BF04AFBE-C6CB-4406-8B67-14E3AA38B9BFQ37610141-9F6BC65B-B5C6-4040-8DEA-B9443CAA2D8FQ37642476-CAB1D2BD-0AB8-4DE5-8C15-C4B62A351E1EQ37670366-B28DEEDC-0C45-4972-B2E1-025F7A23B385Q37694008-20D72FFF-DF65-4B5E-BEBD-CE105FC8EAA7Q38044984-DA9A7009-4BC7-490D-8724-56EB3611D87BQ38145265-21295EAD-1DD9-4ADE-9E6A-853614DE40CAQ38184402-CF7CDE97-34BE-4880-97FC-B82CADAD53CCQ38190099-47E9F330-E897-45AB-B991-1F063A975311Q38200333-7A0E75E0-8795-4231-97B9-F43D15488EB1Q38209074-D09A3094-52F6-4A12-9B68-8FB2D8367D20Q38209177-4404B7DC-71E5-44FB-94CE-B97B69292918Q38214097-9CED0309-28DC-44F6-9D8B-6E58F300318BQ38573100-00188CD5-69B1-4DA7-84D2-AEFC51DDD9B3Q38617373-2A168472-BA43-461B-B2F0-C8516F61376FQ38959942-82D16BC9-1D39-4D6E-89EF-9368DC881957Q39319793-B24F5375-B2DD-4EF8-BC87-3464AFA4F717
P2860
Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cardiorenal actions of TRV1200 ...... ategy for acute heart failure.
@ast
Cardiorenal actions of TRV1200 ...... ategy for acute heart failure.
@en
Cardiorenal actions of TRV1200 ...... ategy for acute heart failure.
@nl
type
label
Cardiorenal actions of TRV1200 ...... ategy for acute heart failure.
@ast
Cardiorenal actions of TRV1200 ...... ategy for acute heart failure.
@en
Cardiorenal actions of TRV1200 ...... ategy for acute heart failure.
@nl
prefLabel
Cardiorenal actions of TRV1200 ...... ategy for acute heart failure.
@ast
Cardiorenal actions of TRV1200 ...... ategy for acute heart failure.
@en
Cardiorenal actions of TRV1200 ...... ategy for acute heart failure.
@nl
P2093
P1476
Cardiorenal actions of TRV1200 ...... ategy for acute heart failure.
@en
P2093
David G Soergel
Erin J Whalen
Guido Boerrigter
John C Burnett
Jonathan D Violin
Michael W Lark
P304
P356
10.1161/CIRCHEARTFAILURE.111.962571
P577
2011-08-11T00:00:00Z